Abstract: A great deal of time and computational resources may be used when developing a machine learning or other data processing workflow. This can be related to the need to re-compute the workflow in response to adjustments to the workflow parameters, in order to assess the benefit of such adjustments so as to develop a workflow that satisfies accuracy or other constraints. Embodiments herein provide time and computational savings by selectively storing and re-loading intermediate results of steps of a data processing workflow. For each step of the workflow, during execution, a decision is made whether to store the intermediate results of the step. Thus, these embodiments can offer storage savings as well as processing speedups when repeatedly re-executing machine learning or other data processing workflows during workflow development.

Abstract: Methods of increasing the resistance of plants, in particular soybeans, to nematodes, in particular soybean cyst nematodes, are provided herein. The methods include increasing the expression of Glyma18g02580, Glyma18g02590 and/or Glyma18g2610 in cells of a plant and in particular in root cells of a plant to increase the resistance of the plant and plant cells to nematodes. The methods include increasing the expression using constitutive promoters or by increasing the copy number of the polynucleotides. Constructs for expressing these polypeptides, transgenic cells, transgenic plants and methods of generating the same are also provided. Methods of screening plant cells for resistance or susceptibility to nematodes are also provided.

Abstract: This invention is benzothiophene-based selective mixed estrogen receptor downregulators and their compositions and uses to treat estrogen-related disorders.

Abstract: Methods for obtaining a tomographic phase image of a specimen, either in transmission or in scatter. A specimen is illuminated by a temporally incoherent source and light collected in transmission or scattering is used to generate a scattered phase image of the specimen in multiple axial planes. The scattered field is solved for in wavevector space, and a derived instrument function is deconvolved to obtain specimen susceptibility in wavevector space. The specimen susceptibility is transformed to obtain a three-dimensional phase tomogram of the specimen.

Abstract: A sLASER-first-COSY sequence is disclosed. After a delay time, ?1, from application of a first 90° radio frequency (RF) pulse, a first pair of adiabatic full-passage (AFP) pulses are applied to an object in a MRI scanner. The first 90° RF pulse is a non-adiabatic slice-selective 90° RF pulse and the first pair of AFP pulses is separated by an inter-pulse time interval, ?2. A second pair of AFP pulses, separated by the time ?2, is then applied, followed by a second 90° RF pulse. The second 90° RF pulse is a non-adiabatic non-slice-selective 90° RF pulse. MR signal is acquired after an echo time (TE) from application of the excitation RF pulse. The present method may achieve intended full magnetization transfer between a coupled spin pair of a metabolite and maintain metabolite cross peak intensity of a coupled spin pair of a metabolite in the object.

Abstract: The invention disclosed herein provides methods for implementing Sampling Interval Modulation Magnetic Resonance Elastography (“SLIM-MRE”), based on simultaneous encoding and acquisition of individual displacement components using motion encoding gradients with different time discretization intervals to MRI analysis. The components are modulated with different frequencies in the MR signal phase, which can be expressed as a harmonic function of the start time, or equivalently of initial phase, of the motion encoding gradient components. As a result, all displacement components can be acquired faster than in conventional MRE, and can be derived from the same temporally-resolved MR phase images. This also allows for simultaneously acquired 3D displacement data and storage of such data in the same k-space.

Abstract: Compounds of Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compounds are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.

Abstract: An array of microcavity plasma devices is formed in a unitary sheet of oxide with embedded microcavities or microchannels and encapsulated metal driving electrodes isolated by oxide from the microcavities or microchannels and arranged so as to generate sustain a plasma in the embedded microcavities or microchannels upon application of time-varying voltage when a plasma medium is contained in the microcavities or microchannels.

Abstract: The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with altered or enhanced activity and broader substrate specificity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activities. Furthermore, the invention provides antibody-conjugated enzymes, pharmaceutical composition and kit containing the same, that can be specifically delivered to tumor cells.

Abstract: The methods and apparatus of the present invention allow the evaluation of inflammation of the esophagus. Measurements may be utilized, for example, to diagnose a disease of the esophagus, to monitor inflammation of the esophagus, or to access the treatment of a disease of the esophagus. In one embodiment, the invention comprises a method for measuring esophageal inflammation comprising deploying a device into the esophagus of a subject, removing the device after a predetermined period of time, analyzing the device for a diagnostic indicator of esophageal inflammation and evaluating the diagnostic indicator to diagnose esophageal inflammation.

Abstract: The invention provides a quantum well active region for an optoelectronic device. The quantum well active region includes barrier layers of high bandgap material. A quantum well of low bandgap material is between the barrier layers. Three-dimensional high bandgap barriers are in the quantum well. A preferred semiconductor laser of the invention includes a quantum well active region of the invention. Cladding layers are around the quantum well active region, as well as a waveguide structure.

Abstract: The invention provides methods for inhibiting tumor cell proliferation by inhibiting Fox M1B (also called Fox M1) activity in a tumor cell. The invention also provides FoxM1B siRNA molecules and pharmaceutical compositions comprising FoxM1B siRNA molecules, wherein the siRNA molecules can inhibit FoxM1B activity and can inhibit proliferation of tumor cells. The invention further provides methods for preventing tumor growth, progression or both in an animal comprising inhibiting FoxM1B activity using siRNA molecules or pharmaceutical compositions comprising FoxM1B siRNA molecules.

Abstract: This invention relates to antibodies that specific bind to fetal CD36+ cells in preference to binding to maternal CD36+ cells and methods for using these antibodies to detect and separate fetal cells from adult biological fluids including maternal peripheral blood.

Abstract: A thromboplastin reagent comprises: (i) activated sTF, (ii) a metal-chelating lipid, (iii) a metal ion, and (iv) a phospholipid. Activated sTF preferably includes the extracellular domain of TF and an oligohistidine moiety having at least 2 histidine residues, more preferably 2-10 histidine residues. Preferably, the histidine residues are consecutive. Attaching a metal binding domain, such as an oligohistidine tag, to the C-terminus of sTF allows the protein to bind to phospholipid vesicles that contain metal-chelating lipid. Metal complexes of this activated sTF and metal-chelating lipids have all of the desirable expression, handling, and solubility characteristics of sTF, and exhibit procoagulant activities in plasma clotting tests that are comparable to relipidated rTF. In addition, it was discovered that, under some circumstances, Ni-lipids are themselves procoagulant, even in the absence of activated sTF.

Abstract: A hybridoma (termed “UIC2 hybridoma”, ATCC Accession No. HB11027) producing monoclonal antibodies (termed “UIC2 mAb”) directed against an extracellular domain of a cell surface P-glycoprotein antigen associated with multidrug resistance in primate cells was produced by fusing a human myeloma cell with a spleen cell derived from a BALB/c mouse immunized with syngeneic 3T3 fibroblasts previously transfected with the isolated human mdrl cDNA. UIC2 mAb, thus produced, as well as fragments and recombinant derivatives thereof, may be used to detect and isolate multidrug resistant primate cells and human mdrl gene products, and to reverse multidrug resistance in primate cells, including cells of multidrug resistant human tumors.

Abstract: Disclosed is a synthetic method for the preparation of analogs of Didemnin A (1), particularly the Amino-Hip analog of Didemnin A, also known as “AipDidemnin A” (8).